Royal London Asset Management Ltd. Sells 2,497 Shares of Amgen Inc. $AMGN

Royal London Asset Management Ltd. trimmed its holdings in Amgen Inc. (NASDAQ:AMGN) by 0.9% in the fourth quarter, HoldingsChannel reports. The fund owned 279,279 shares of the medical research company’s stock after selling 2,497 shares during the period. Royal London Asset Management Ltd.’s holdings in Amgen were worth $91,411,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the business. Vanguard Group Inc. lifted its holdings in shares of Amgen by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after acquiring an additional 961,975 shares during the last quarter. Capital World Investors lifted its holdings in shares of Amgen by 22.9% in the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after acquiring an additional 4,302,237 shares during the last quarter. Capital International Investors lifted its holdings in shares of Amgen by 1.5% in the 3rd quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock worth $5,414,296,000 after acquiring an additional 282,219 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Amgen by 7.8% in the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after acquiring an additional 1,035,779 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Amgen in the 4th quarter worth approximately $2,164,162,000. 76.50% of the stock is currently owned by institutional investors.

Amgen Stock Performance

Shares of Amgen stock opened at $355.20 on Friday. The stock has a market cap of $191.70 billion, a price-to-earnings ratio of 24.72, a PEG ratio of 3.55 and a beta of 0.42. The firm’s 50-day moving average is $340.97 and its 200 day moving average is $345.72. Amgen Inc. has a 1 year low of $267.83 and a 1 year high of $391.29. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The company had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. Amgen’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Sell-side analysts anticipate that Amgen Inc. will post 22.38 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Argus lowered their price objective on shares of Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a report on Wednesday, May 20th. Truist Financial upped their target price on shares of Amgen from $325.00 to $327.00 and gave the stock a “hold” rating in a research report on Friday, May 1st. Daiwa Securities Group reduced their target price on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 13th. The Goldman Sachs Group set a $389.00 target price on shares of Amgen in a research report on Friday, June 5th. Finally, Jefferies Financial Group assumed coverage on shares of Amgen in a research report on Tuesday, March 10th. They issued a “hold” rating and a $350.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $354.12.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen said its phase 3 ABP 938 eye-disease study is advancing, with the drug aimed at challenging Regeneron’s Eylea HD in a major retina market. That keeps Amgen’s pipeline in focus as a potential future growth driver. Article Title
• Positive Sentiment: Amgen also highlighted its MARITIME-SWITCH phase 3 obesity trial, which is designed to capture GLP-1 switchers. Any success in obesity treatment could open another large market and improve long-term revenue expectations. Article Title
• Positive Sentiment: Some coverage pointed to Amgen as a value stock with supportive new data from the VESALIUS-CV cardiovascular study for Repatha, reinforcing confidence in the company’s broader portfolio. Article Title
• Neutral Sentiment: Amgen and outside analysts published bullish commentary on the stock’s valuation and earnings profile, but these were mostly opinion pieces rather than new business developments. Article Title
• Negative Sentiment: Investor sentiment is being pressured by reports that Amgen’s Tavneos faces a proposed FDA withdrawal, with the company seeking a hearing and commissioning an independent review to defend the drug’s data. Regulatory uncertainty around a $500 million product is a meaningful risk for the stock. Article Title
• Negative Sentiment: Reuters also reported that Amgen hired a research firm to reassess Tavneos data after FDA concerns, underscoring the regulatory overhang and near-term uncertainty for the drug. Article Title

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. The trade was a 15.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.85% of the stock is currently owned by insiders.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.